

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use DISKETTS safely and effectively. See full prescribing information for DISKETTS.

DISKETTS Dispersible Tablets (methadone hydrochloride tablets for oral suspension) CII  
Initial U.S. Approval: 1973

**WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION, LIFE-THREATENING QT PROLONGATION, ACCIDENTAL EXPOSURE, ABUSE POTENTIAL and TREATMENT FOR OPIOID ADDICTION**

*See full prescribing information for complete boxed warning*

- Fatal respiratory depression may occur, with highest risk at initiation and with dose increases. Instruct patients on proper administration of DISKETTS Dispersible Tablets to reduce the risk. (5.1)
- QT Interval prolongation and serious arrhythmia (torsades de pointes) have occurred with treatment with methadone. (5.2)
- Accidental ingestion of DISKETTS Dispersible Tablets can result in fatal overdose of methadone, especially in children. (5.3)
- DISKETTS Dispersible Tablets contain methadone, a Schedule II controlled substance and can be abused and criminally diverted. (5.4, 9)
- Methadone products, when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed only by certified opioid treatment programs as stipulated in 42 CFR 8.12. (1)

**INDICATIONS AND USAGE**

DISKETTS Dispersible Tablets are an opioid agonist indicated for the:

- Detoxification treatment of opioid addiction (heroin or other morphine-like drugs) (1)
- Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. (1)

**DOSAGE AND ADMINISTRATION**

- Initiation of detoxification and maintenance treatment: A single dose of 20 to 30 mg may be sufficient to suppress withdrawal syndrome. (2.1)
- Do not abruptly discontinue DISKETTS Dispersible Tablets in a physically dependent patient (2.3, 5.12)
- Maintenance treatment: Clinical stability is most commonly achieved at doses between 80 to 120 mg/day. (2.2)

**DOSAGE FORMS AND STRENGTHS**

Tablets intended for dispersion in a liquid immediately prior to oral administration: 40 mg. (3)

**CONTRAINDICATIONS**

- Significant respiratory depression (4)
- Acute or severe bronchial asthma (4)
- Known or suspected paralytic ileus (4)
- Known hypersensitivity to methadone (4)

**WARNINGS AND PRECAUTIONS**

- Elderly, cachectic, and debilitated patients, and patients with chronic pulmonary disease: Monitor closely because of increased risk of respiratory depression. (5.5, 5.6)
- Interactions with CNS depressants: Consider dose reduction of one or both drugs because of additive effects. (5.7, 7.2)
- Hypotensive effect: Monitor during dose initiation and titration. (5.8)
- Patients with head injury and increased intracranial pressure: Monitor for sedation and respiratory depression. Avoid use of methadone in patients with impaired consciousness or coma susceptible to intracranial effects of CO<sub>2</sub> retention (5.9)

**ADVERSE REACTIONS**

Most common adverse reactions are: lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Roxane Laboratories, Inc. at 800-962-8364 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch)

**DRUG INTERACTIONS**

- CYP3A4 Inducers: Increased risk of more rapid metabolism and decreased effects of methadone. (7.1)
- CYP3A4 Inhibitors: Increased risk of reduced metabolism and methadone toxicity. (7.1)
- Anti-retroviral Agents: May result in increased clearance and decreased plasma levels of methadone or in certain cases, increased plasma levels and risk of toxicity. (7.1)
- Potentially Arrhythmogenic Agents: Extreme caution is necessary when any drug known to have the potential to prolong the QT interval is prescribed in conjunction with methadone. (7.3)
- Opioid antagonists, partial agonists, mixed agonists/antagonist opioid analgesics: Avoid concomitant use with DISKETTS Dispersible Tablets because it may precipitate withdrawal symptoms. (5.12, 7.4)

**USE IN SPECIFIC POPULATIONS**

- Pregnancy: Based on animal data, may cause fetal harm. (8.1)
- Nursing mothers: Methadone has been detected in human milk. Closely monitor infants of nursing women receiving DISKETTS Dispersible Tablets. (8.3)

See 17 for PATIENT COUNSELING INFORMATION

Revised: 9/2013

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION, LIFE-THREATENING QT PROLONGATION, ACCIDENTAL EXPOSURE, ABUSE POTENTIAL and TREATMENT FOR OPIOID ADDICTION**

1	INDICATIONS AND USAGE
2	DOSAGE AND ADMINISTRATION
2.1	Induction/Initial Dosing for Detoxification and Maintenance Treatment of Opioid Addiction
2.2	Titration and Maintenance Treatment of Opioid Dependence
2.3	Medically Supervised Withdrawal After a Period of Maintenance Treatment for Opioid Addiction
2.4	Risk of Relapse in Patients on Methadone Maintenance Treatment of Opioid Addiction
2.5	Considerations for Management of Acute Pain During Methadone Maintenance Treatment
2.6	Dosage Adjustment During Pregnancy
3	DOSAGE FORMS AND STRENGTHS
4	CONTRAINDICATIONS
5	WARNINGS AND PRECAUTIONS
5.1	Life-Threatening Respiratory Depression
5.2	Life-Threatening QT Prolongation
5.3	Accidental Exposure
5.4	Abuse Potential

5.5	Elderly, Cachectic, and Debilitated Patients
5.6	Use in Patients with Chronic Pulmonary Disease
5.7	Interactions with CNS Depressants and Illicit Drugs
5.8	Hypotensive Effect
5.9	Use in Patients with Head Injury or Increased Intracranial Pressure
5.10	Use in Patients with Gastrointestinal Conditions
5.11	Use in Patients with Convulsive or Seizure Disorders
5.12	Avoidance of Withdrawal
5.13	Driving and Operating Machinery
6	ADVERSE REACTIONS
7	DRUG INTERACTIONS
7.1	Cytochrome P450 Interactions
7.2	CNS Depressants
7.3	Potentially Arrhythmogenic Agents
7.4	Opioid Antagonists, Mixed Agonists/Antagonists, and Partial Agonists
7.5	Antidepressants
7.6	Anticholinergics
7.7	Laboratory Test Interactions
8	USE IN SPECIFIC POPULATIONS
8.1	Pregnancy
8.2	Labor and Delivery
8.3	Nursing Mothers
8.4	Pediatric Use
8.5	Geriatric Use
8.6	Neonatal Opioid Withdrawal Syndrome

- 8.7 Renal Impairment
- 8.8 Hepatic Impairment
- 9 DRUG ABUSE AND DEPENDENCE**
  - 9.1 Controlled Substance
  - 9.2 Abuse
  - 9.3 Dependence
- 10 OVERDOSAGE**
- 11 DESCRIPTION**
- 12 CLINICAL PHARMACOLOGY**
  - 12.1 Mechanism of Action
  - 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY**
  - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 16 HOW SUPPLIED/STORAGE AND HANDLING**
  - 16.1 Storage and Handling
  - 16.2 How Supplied
- 17 PATIENT COUNSELING INFORMATION**

\*Sections or subsections omitted from the full prescribing information are not listed

---

## FULL PRESCRIBING INFORMATION

### **WARNING: LIFE-THREATENING RESPIRATORY DEPRESSION, LIFE-THREATENING QT PROLONGATION, ACCIDENTAL EXPOSURE, ABUSE POTENTIAL and TREATMENT FOR OPIOID ADDICTION**

#### **Life-threatening Respiratory Depression**

Respiratory depression, including fatal cases, have been reported during initiation and conversion of patients to methadone, and even when the drug has been used as recommended and not misused or abused [see *Warnings and Precautions (5.1)*]. Proper dosing and titration are essential and DISKETS Dispersible Tablets should only be prescribed by healthcare professionals who are knowledgeable in the use of methadone for detoxification and maintenance treatment of opioid addiction. Monitor for respiratory depression, especially during initiation of DISKETS Dispersible Tablets or following a dose increase. The peak respiratory depressant effect of methadone occurs later, and persists longer than the peak pharmacologic effect, especially during the initial dosing period.

#### **Life-Threatening QT Prolongation**

QT interval prolongation and serious arrhythmia (torsades de pointes) have occurred during treatment with methadone [see *Warnings and Precautions (5.2)*]. Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. Closely monitor patients for changes in cardiac rhythm during initiation and titration of DISKETS Dispersible Tablets.

#### **Accidental Exposure**

Accidental ingestion of DISKETS Dispersible Tablets, especially in children, can result in fatal overdose of methadone [see *Warnings and Precautions (5.3)*].

#### **Abuse Potential**

DISKETS Dispersible Tablets contain methadone, an opioid agonist and Schedule II controlled substance with an abuse liability similar to other opioid agonists, legal or illicit [see *Warnings and Precautions (5.4)*]. Routinely monitor all patients receiving DISKETS for signs of misuse, abuse, and addiction during treatment [see *Drug Abuse and Dependence (9)*].

#### **Conditions For Distribution And Use Of Methadone Products For The Treatment of Opioid Addiction**

For detoxification and maintenance of opioid dependence, methadone should be administered in accordance with the treatment standards cited in 42 CFR Section 8, including limitations on unsupervised administration [see *Indications and Usage (1)*].

## 1 INDICATIONS AND USAGE

DISKETS Dispersible Tablets contain methadone, an opioid agonist indicated for the:

- Detoxification treatment of opioid addiction (heroin or other morphine-like drugs).
- Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services.

**Conditions For Distribution And Use Of Methadone Products For The Treatment Of Opioid Addiction**  
Code of Federal Regulations, Title 42, Sec 8

Methadone products when used for the treatment of opioid addiction in detoxification or maintenance programs, shall be dispensed only by opioid treatment programs (and agencies, practitioners or institutions by formal agreement with the program sponsor) certified by the Substance Abuse and Mental Health Services Administration and approved by the designated state authority. Certified treatment programs shall dispense and use methadone in oral form only and according to the treatment requirements stipulated in the Federal Opioid Treatment Standards (42 CFR 8.12). See below for important regulatory exceptions to the general requirement for certification to provide opioid agonist treatment.

Failure to abide by the requirements in these regulations may result in criminal prosecution, seizure of the drug supply, revocation of the program approval, and injunction precluding operation of the program.

**Regulatory Exceptions To The General Requirement For Certification To Provide Opioid Agonist Treatment:** During inpatient care, when the patient was admitted for any condition other than concurrent opioid addiction (pursuant to 21CFR 1306.07(c)), to facilitate the treatment of the primary admitting diagnosis.

During an emergency period of no longer than 3 days while definitive care for the addiction is being sought in an appropriately licensed facility (pursuant to 21CFR 1306.07(b)).

## **2 DOSAGE AND ADMINISTRATION**

Consider the following important factors that differentiate methadone from other opioids:

- The peak respiratory depressant effect of methadone occurs later and persists longer than its peak pharmacologic effect.
- A high degree of opioid tolerance does not eliminate the possibility of methadone overdose, iatrogenic or otherwise. Deaths have been reported during conversion to methadone from chronic, high-dose treatment with other opioid agonists and during initiation of methadone treatment of addiction in subjects previously abusing high doses of other opioid agonists.
- There is high interpatient variability in absorption, metabolism, and relative analgesic potency. Population-based conversion ratios between methadone and other opioids are not accurate when applied to individuals.
- With repeated dosing, methadone is retained in the liver and then slowly released, prolonging the duration of potential toxicity.
- Steady-state plasma concentrations are not attained until 3 to 5 days after initiation of dosing.
- Methadone has a narrow therapeutic index, especially when combined with other drugs.

### **2.1 Induction/Initial Dosing for Detoxification and Maintenance Treatment of Opioid Addiction**

For detoxification and maintenance of opioid dependence methadone should be administered in accordance with the treatment standards cited in 42 CFR Section 8.12, including limitations on unsupervised administration.

DISKETS are intended for dispersion in a liquid immediately prior to oral administration of the prescribed dose. The tablets should not be chewed or swallowed before dispersing in liquid. DISKETS are cross-scored, allowing for flexible dosage adjustment. Each cross-scored tablet may be broken or cut in half to yield two 20-mg doses, or in quarters to yield four 10-mg doses. Prior to administration, the desired dose of DISKETS should be dispersed in approximately 120 mL (4 ounces) of water, orange juice, or other acidic fruit beverage prior to taking. Methadone hydrochloride is very soluble in water, but there are some insoluble excipients that will not entirely dissolve. If residue remains in the cup after initial administration, a small amount of liquid should be added and the resulting mixture administered to the patient.

Administer the initial methadone dose under supervision, when there are no signs of sedation or intoxication, and the patient shows symptoms of withdrawal. An initial single dose of 20 to 30 mg of methadone will often be sufficient to suppress withdrawal symptoms. The initial dose should not exceed 30 mg.

To make same-day dosing adjustments, have the patient wait 2 to 4 hours for further evaluation, when peak levels have been reached. Provide an additional 5 to 10 mg of methadone if withdrawal symptoms have not been suppressed or if symptoms reappear.

The total daily dose of methadone on the first day of treatment should not ordinarily exceed 40 mg. Adjust the dose over the first week of treatment based on control of withdrawal symptoms at the time of expected peak activity (i.e., 2 to 4 hours after dosing). When adjusting the dose, keep in mind that methadone will accumulate over the first several days of dosing; deaths have occurred in early treatment due to the cumulative effects. Because DISKETS can be administered only in 10 mg increments, DISKETS may not be the appropriate product for initial dosing in many patients. Instruct patients that the dose will “hold” for a longer period of time as tissue stores of methadone accumulate.

Use lower initial doses for patients whose tolerance is expected to be low at treatment entry. Any patient who has not taken opioids for more than 5 days may no longer be tolerant. Do not determine initial doses based on previous treatment episodes or dollars spent per day on illicit drug use. Also consider concurrent medications and the general condition and medical status of the patient when selecting the initial dose.

### ***Short-term Detoxification***

For a brief course of stabilization followed by a period of medically supervised withdrawal, titrate the patient to a total daily dose of about 40 mg in divided doses to achieve an adequate stabilizing level. After 2 to 3 days of stabilization, gradually decrease the dose of methadone. Decrease the dose of methadone on a daily basis or at 2-day intervals, keeping the amount of methadone sufficient to keep withdrawal symptoms at a tolerable level. Hospitalized patients may tolerate a daily reduction of 20% of the total daily dose. Ambulatory patients may need a slower schedule. Because DISKETS can be administered only in 10 mg increments, DISKETS may not be the appropriate product for gradual dose reduction in many patients.

## **2.2 Titration and Maintenance Treatment of Opioid Dependence**

Titrate patients in maintenance treatment to a dose that prevents opioid withdrawal symptoms for 24 hours, reduces drug hunger or craving, and blocks or attenuates the euphoric effects of self-administered opioids, ensuring that the patient is tolerant to the sedative effects of methadone. Most commonly, clinical stability is achieved at doses between 80 to 120 mg/day.

## **2.3 Medically Supervised Withdrawal After a Period of Maintenance Treatment for Opioid Addiction**

There is considerable variability in the appropriate rate of methadone taper in patients choosing medically supervised withdrawal from methadone treatment. Dose reductions should generally be less than 10% of the established tolerance or maintenance dose, and 10 to 14-day intervals should elapse between dose reductions. Because DISKETS can be administered only in 10 mg increments, it may not be the appropriate product for gradual dose reduction in many patients. Apprise patients of the high risk of relapse to illicit drug use associated with discontinuation of methadone maintenance treatment.

## **2.4 Risk of Relapse in Patients on Methadone Maintenance Treatment of Opioid Addiction**

Abrupt opioid discontinuation can lead to development of opioid withdrawal symptoms [see *Drug Abuse and Dependence (9.3)*]. Opioid withdrawal symptoms have been associated with an increased risk of relapse to

illicit drug use in susceptible patients.

## 2.5 Considerations for Management of Acute Pain During Methadone Maintenance Treatment

Patients in methadone maintenance treatment for opioid dependence who experience physical trauma, postoperative pain or other acute pain cannot be expected to derive analgesia from their existing dose of methadone. Such patients should be administered analgesics, including opioids, in doses that would otherwise be indicated for non-methadone-treated patients with similar painful conditions. When opioids are required for management of acute pain in methadone maintenance patients, somewhat higher and/or more frequent doses will often be required than would be the case for non-tolerant patients due to the opioid tolerance induced by methadone.

## 2.6 Dosage Adjustment During Pregnancy

Methadone clearance may be increased during pregnancy. During pregnancy, a woman's methadone dose may need to be increased or the dosing interval decreased. Methadone should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus [see *Use in Specific Populations (8.1)*].

## 3 DOSAGE FORMS AND STRENGTHS

Each 40 mg dispersible tablet for oral administration following dispersion in a liquid contains: 40 mg of methadone hydrochloride and is a pillow-shaped, light-pinkish orange compressed dispersible tablet. DISKETTS are cross-scored, allowing for flexible dosage adjustment. Each tablet may be broken or cut in half to yield two 20-mg doses, or in quarters to yield four 10-mg doses.

## 4 CONTRAINDICATIONS

DISKETTS Dispersible Tablets are contraindicated in patients with:

- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected paralytic ileus
- Hypersensitivity (e.g. anaphylaxis) to methadone or any other ingredient in DISKETTS Dispersible Tablets [see *Adverse Reactions (6)*]

## 5 WARNINGS AND PRECAUTIONS

**DISKETTS Dispersible Tablets are for oral administration only. The preparation must not be injected. Methadone should be kept out of reach of children to prevent accidental ingestion.**

### 5.1 Life-Threatening Respiratory Depression

Respiratory depression is the primary risk of methadone. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Respiratory depression from opioids is manifested by a reduced urge to breathe and a decreased rate of respiration, often associated with a "sighing" pattern of breathing (deep breaths separated by abnormally long pauses). Carbon dioxide (CO<sub>2</sub>) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status [see *Overdosage (10)*].

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of methadone, the risk is greatest during the initiation of therapy or following a dose increase. **The peak**

**respiratory depressant effect of methadone occurs later, and persists longer than the peak pharmacologic effect, especially during the initial dosing period.** Closely monitor patients with respiratory depression when initiating therapy with methadone and following dose increases.

Instruct patients against use by individuals other than the patient for whom methadone was prescribed and to keep methadone out of the reach of children, as such inappropriate use may result in fatal respiratory depression.

To reduce the risk of respiratory depression, proper dosing and titration of methadone are essential [see *Dosage and Administration (2.1)*]. Overestimating the methadone dose when converting patients from another opioid product can result in fatal overdose with the first dose. Respiratory depression has also been reported with use of methadone when used as recommended and not misused or abused.

To further reduce the risk of respiratory depression, consider the following:

- **Patients tolerant to other opioids may be incompletely tolerant to methadone.** Incomplete cross-tolerance is of particular concern for patients tolerant to other mu-opioid agonists who are being converted to treatment with methadone, thus making determination of dosing during opioid treatment conversion complex. **Deaths have been reported during conversion from chronic, high-dose treatment with other opioid agonists.**
- **Proper dosing and titration are essential** and methadone should be prescribed only by healthcare professionals who are knowledgeable in the pharmacokinetics and pharmacodynamics of methadone.
- Methadone is contraindicated in patients with respiratory depression and in patients with conditions that increase the risk of life-threatening respiratory depression [see *Contraindications (4)*].

## 5.2 Life-Threatening QT Prolongation

Cases of QT interval prolongation and serious arrhythmia (torsades de pointes) have been observed during treatment with methadone. These cases appear to be more commonly associated with, but not limited to, higher dose treatment (> 200 mg/day). Most cases involve patients being treated for pain with large, multiple daily doses of methadone, although cases have been reported in patients receiving doses commonly used for maintenance treatment of opioid addiction. In most patients on the lower doses typically used for maintenance, concomitant medications and/or clinical conditions such as hypokalemia were noted as contributing factors. However, the evidence strongly suggests that methadone possesses the potential for adverse cardiac conduction effects in some patients. The effects of methadone on the QT interval have been confirmed in *in vivo* laboratory studies, and methadone has been shown to inhibit cardiac potassium channels in *in vitro* studies.

Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. QT prolongation has also been reported in patients with no prior cardiac history who have received high doses of methadone.

Evaluate patients developing QT prolongation while on DISKETTS Dispersible Tablets treatment for the presence of modifiable risk factors, such as concomitant medications with cardiac effects, drugs which might cause electrolyte abnormalities, and drugs which might act as inhibitors of methadone metabolism.

Only initiate therapy with DISKETTS Dispersible Tablets in patients for whom the anticipated benefit outweighs the risk of QT prolongation and development of dysrhythmias that have been reported with high doses of methadone. The use of methadone in patients already known to have a prolonged QT interval has not been systematically studied.

### **5.3 Accidental Exposure**

Accidental ingestion of DISKETTS Dispersible Tablets, especially in children, can result in a fatal overdose of methadone. DISKETTS Dispersible Tablets should be kept out of reach of children to prevent accidental ingestion.

### **5.4 Abuse Potential**

DISKETTS Dispersible Tablets contain methadone, an opioid agonist and a Schedule II controlled substance. Methadone can be abused in a manner similar to other opioid agonists, legal or illicit. Opioid agonists are sought by drug abusers and people with addiction disorders and are subject to criminal diversion.

Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.

### **5.5 Elderly, Cachectic, and Debilitated Patients**

Respiratory depression is more likely to occur in elderly, cachectic, or debilitated patients as they may have altered pharmacokinetics due to poor fat stores, muscle wasting, or altered clearance compared to younger, healthier patients. Therefore, monitor such patients closely, particularly when initiating and titrating DISKETTS Dispersible Tablets and when DISKETTS Dispersible Tablets are given concomitantly with other drugs that depress respiration [*see Warnings and Precautions (5.1)*].

### **5.6 Use in Patients with Chronic Pulmonary Disease**

Monitor patients with significant chronic obstructive pulmonary disease or cor pulmonale, and patients having a substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression, particularly when initiating therapy and titrating with DISKETTS Dispersible Tablets, as in these patients, even usual therapeutic doses of methadone may decrease respiratory drive to the point of apnea [*see Warnings and Precautions (5.1)*].

### **5.7 Interactions with CNS Depressants and Illicit Drugs**

Hypotension, profound sedation, coma, or respiratory depression may result if methadone is used concomitantly with other CNS depressants (e.g., sedatives, anxiolytics, hypnotics, neuroleptics, other opioids). When considering the use of DISKETTS Dispersible Tablets in a patient taking a CNS depressant, assess the duration of use of the CNS depressant and the patient's response, including the degree of tolerance that has developed to CNS depression. Additionally, consider the patient's use, if any, of alcohol or illicit drugs that cause CNS depression. If methadone therapy is to be initiated in a patient taking a CNS depressant, start with a lower methadone dose than usual and monitor patients for signs of sedation and respiratory depression and consider using a lower dose of the concomitant CNS depressant [*see Drug Interactions (7.2)*].

Deaths associated with illicit use of methadone have frequently involved concomitant benzodiazepine abuse.

### **5.8 Hypotensive Effect**

Methadone may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is an increased risk in patients whose ability to maintain normal blood pressure is compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g. phenothiazines or general anesthetics) [*see Drug Interactions (7.2)*]. Monitor these patients for signs of hypotension after initiating or titrating the dose of DISKETTS Dispersible Tablets.

## 5.9 Use in Patients with Head Injury or Increased Intracranial Pressure

Monitor patients taking DISKETS Dispersible Tablets who may be susceptible to the intracranial effects of CO<sub>2</sub> retention (e.g. those with evidence of increased intracranial pressure or brain tumors) for signs of sedation and respiratory depression, particularly when initiating therapy with methadone. Methadone may reduce respiratory drive, and the resultant CO<sub>2</sub> retention can further increase intracranial pressure. Opioids may also obscure the clinical course in a patient with a head injury.

Avoid the use of methadone in patients with impaired consciousness or coma.

## 5.10 Use in Patients with Gastrointestinal Conditions

DISKETS Dispersible Tablets are contraindicated in patients with paralytic ileus. Avoid the use of DISKETS Dispersible Tablets in patients with other gastrointestinal obstruction.

Methadone may cause spasm of the sphincter of Oddi. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms. Opioids may cause increases in the serum amylase.

## 5.11 Use in Patients with Convulsive or Seizure Disorders

Methadone may aggravate convulsions in patients with convulsive disorders, and may induce or aggravate seizures in some clinical settings. Monitor patients with a history of seizure disorders for worsened seizure control during DISKETS Dispersible Tablets therapy.

## 5.12 Avoidance of Withdrawal

Avoid the use of partial agonists or mixed agonist/antagonist analgesics (i.e., buprenorphine, pentazocine, nalbuphine, and butorphanol) in patients who have received or are receiving a course of therapy with a full opioid agonist analgesic, including methadone. In these patients, partial agonists or mixed agonists/antagonists analgesics may precipitate withdrawal symptoms [*see Drug Interactions (7.4)*].

When discontinuing DISKETS Dispersible Tablets, gradually taper the dose [*see Dosage and Administration (2.3, 2.4)*]. Do not abruptly discontinue DISKETS Dispersible Tablets.

## 5.13 Driving and Operating Machinery

Methadone may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of DISKETS Dispersible Tablets and know how they will react to the medication.

## 6 ADVERSE REACTIONS

The following adverse reactions have been identified during post-approval use of methadone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following serious adverse reactions and/or conditions are discussed elsewhere in the labeling:

- Respiratory Depression [*see Warnings and Precautions (5.1)*]
- QT Prolongation [*see Warnings and Precautions (5.2)*]
- Chronic Pulmonary Disease [*see Warnings and Precautions (5.6)*]
- Interactions with CNS Depressants [*see Warnings and Precautions (5.7)*]

- Hypotensive Effect [*see Warnings and Precautions (5.8)*]
- Head Injuries and Increased Intracranial Pressure [*see Warnings and Precautions (5.9)*]
- Gastrointestinal Effects [*see Warnings and Precautions (5.10)*]
- Seizures [*see Warnings and Precautions (5.11)*]

**The major hazards of methadone are respiratory depression and, to a lesser degree, systemic hypotension. Respiratory arrest, shock, cardiac arrest, and death have occurred.**

The most frequently observed adverse reactions include lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. These effects seem to be more prominent in ambulatory patients and in those who are not suffering severe pain. In such individuals, lower doses are advisable.

Other adverse reactions include the following:

*Body as a Whole:* asthenia (weakness), edema, headache

*Cardiovascular:* arrhythmias, bigeminal rhythms, bradycardia, cardiomyopathy, ECG abnormalities, extrasystoles, flushing, heart failure, hypotension, palpitations, phlebitis, QT interval prolongation, syncope, T-wave inversion, tachycardia, torsade de pointes, ventricular fibrillation, ventricular tachycardia

*Central Nervous System:* agitation, confusion, disorientation, dysphoria, euphoria, insomnia, hallucinations, seizures, visual disturbances

*Endocrine:* hypogonadism

*Gastrointestinal:* abdominal pain, anorexia, biliary tract spasm, constipation, dry mouth, glossitis

*Hematologic:* reversible thrombocytopenia has been described in opioid addicts with chronic hepatitis

*Metabolic:* hypokalemia, hypomagnesemia, weight gain

*Musculoskeletal:* decreased muscle mass and strength, osteoporosis and fractures

*Renal:* antidiuretic effect, urinary retention or hesitancy

*Reproductive:* amenorrhea, reduced libido and/or potency, reduced ejaculate volume, reduced seminal vesicle and prostate secretions, decreased sperm motility, abnormalities in sperm morphology

*Respiratory:* pulmonary edema, respiratory depression

*Skin and Subcutaneous Tissue:* pruritus, urticaria, other skin rashes, and rarely, hemorrhagic urticaria

*Hypersensitivity:* Anaphylaxis has been reported with ingredients contained in DISKETS Dispersible Tablets. Advise patients how to recognize such a reaction and when to seek medical attention.

*Maintenance on a Stabilized Dose:* During prolonged administration of methadone, as in a methadone maintenance treatment program, constipation and sweating often persist and hypogonadism, decreased serum testosterone and reproductive effects are thought to be related to chronic opioid use.

DISKETS Dispersible Tablets for the Detoxification and Maintenance Treatment of Opioid Dependence

During the induction phase of methadone maintenance treatment, patients are being withdrawn from illicit opioids and may have opioid withdrawal symptoms. Monitor patients for signs and symptoms including: lacrimation, rhinorrhea, sneezing, yawning, excessive perspiration, goose-flesh, fever, chilling alternating with flushing, restlessness, irritability, weakness, anxiety, depression, dilated pupils, tremors, tachycardia, abdominal cramps, body aches, involuntary twitching and kicking movements, anorexia, nausea, vomiting, diarrhea, intestinal spasms, and weight loss and consider dose adjustment as indicated.

## 7 DRUG INTERACTIONS

### 7.1 Cytochrome P450 Interactions

Methadone undergoes hepatic N-demethylation by cytochrome P450 (CYP) isoforms, principally CYP3A4, CYP2B6, CYP2C19, and to a lesser extent by CYP2C9 and CYP2D6 [see *Clinical Pharmacology (12.3)*].

#### *Cytochrome P450 Inducers*

Concurrent use of methadone and drugs that induce cytochrome P450 enzymes (such as rifampicin, phenytoin, phenobarbital, carbamazepine, and St. John's Wort) may result in reduced efficacy of methadone and could precipitate a withdrawal syndrome. Closely monitor patients receiving DISKETTS Dispersible Tablets and an enzyme inducer closely for signs of withdrawal and adjust the methadone dose accordingly.

#### *Cytochrome P450 Inhibitors*

Coadministration of drugs that inhibit CYP3A4 (such as ketoconazole, itraconazole, voriconazole, clarithromycin, erythromycin, telithromycin) and/or drugs that inhibit CYP2C9 (such as sertraline and fluvoxamine) may cause decreased clearance of methadone, which could increase or prolong adverse drug effects and may cause fatal respiratory depression [see *Clinical Pharmacology (12.3)*]. Monitor patients closely for signs of respiratory or central nervous system depression when DISKETTS Dispersible Tablets are prescribed with a CYP3A4 inhibitor and reduce the dosage if necessary.

#### *Paradoxical Effects of Antiretroviral Agents on Methadone*

Concurrent use of certain protease inhibitors with CYP3A4 inhibitory activity, alone and in combination, such as abacavir, amprenavir, darunavir+ritonavir, efavirenz, nelfinavir, nevirapine, ritonavir, telaprevir, lopinavir+ritonavir, saquinavir+ritonavir, and tipranvir+ritonavir, has resulted in **increased clearance** or decreased plasma levels of methadone. This may result in reduced efficacy of DISKETTS Dispersible Tablets and could precipitate a withdrawal syndrome. Monitor patients receiving DISKETTS Dispersible Tablets and any of these anti-retroviral therapies closely for evidence of withdrawal effects and adjust the DISKETTS Dispersible Tablets dose accordingly.

#### *Effects of Methadone on Antiretroviral Agents*

*Didanosine and Stavudine:* Experimental evidence demonstrated that methadone decreased the area under the concentration-time curve (AUC) and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered.

*Zidovudine:* Experimental evidence demonstrated that methadone increased the AUC of zidovudine, which could result in toxic effects.

### 7.2 CNS Depressants

Concurrent use of methadone and other central nervous system (CNS) depressants (e.g. sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, other tranquilizers, alcohol and drugs of abuse) can increase the risk of respiratory depression, hypotension, and profound sedation or coma. Monitor patients receiving CNS depressants and DISKETTS Dispersible Tablets for signs of respiratory depression and hypotension. When such combined therapy is contemplated, reduce the initial dose of one or both agents. Deaths have been reported

when methadone has been abused in conjunction with benzodiazepines.

### 7.3 Potentially Arrhythmogenic Agents

Monitor patients closely for cardiac conduction changes when any drug known to have the potential to prolong the QT interval is prescribed in conjunction with DISKETS Dispersible Tablets. Pharmacodynamic interactions may occur with concomitant use of DISKETS Dispersible Tablets and potentially arrhythmogenic agents such as class I and III antiarrhythmics, some neuroleptics and tricyclic antidepressants, and calcium channel blockers.

Similarly, monitor patients closely when prescribing DISKETS Dispersible Tablets concomitantly with drugs capable of inducing electrolyte disturbances (hypomagnesemia, hypokalemia) that may prolong the QT interval, including diuretics, laxatives, and, in rare cases, mineralocorticoid hormones.

### 7.4 Opioid Antagonists, Mixed Agonist/Antagonists, and Partial Agonists

As with other mu-agonists, patients maintained on methadone may experience withdrawal symptoms when given opioid antagonists, mixed agonist/antagonists, and partial agonists. Examples of such agents are *naloxone*, *naltrexone*, *pentazocine*, *nalbuphine*, *butorphanol*, and *buprenorphine*.

### 7.5 Antidepressants

*Monoamine Oxidase (MAO) Inhibitors:* Therapeutic doses of meperidine have precipitated severe reactions in patients concurrently receiving monoamine oxidase inhibitors or those who have received such agents within 14 days. Similar reactions thus far have not been reported with methadone. However, if the use of DISKETS Dispersible Tablets is necessary in such patients, a sensitivity test should be performed in which repeated small, incremental doses of DISKETS Dispersible Tablets are administered over the course of several hours while the patient's condition and vital signs are carefully observed.

*Desipramine:* Blood levels of desipramine have increased with concurrent methadone administration.

### 7.6 Anticholinergics

Anticholinergics or other drugs with anticholinergic activity when used concurrently with opioids may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor patients for signs of urinary retention or reduced gastric motility when DISKETS Dispersible Tablets are used concurrently with anticholinergic drugs.

### 7.7 Laboratory Test Interactions

False positive urine drug screens for methadone have been reported for several drugs including diphenhydramine, doxylamine, clomipramine, chlorpromazine, thioridazine, quetiapine, and verapamil.

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### Pregnancy Category C

There are no adequate and well controlled studies of methadone use in pregnant women. Methadone has been shown to be teratogenic in the hamster at doses 2 times the human daily oral dose (120 mg/day on a mg/m<sup>2</sup> basis) and in mice at doses equivalent to the human daily oral dose (120 mg/day on a mg/m<sup>2</sup> basis). Increased neonatal mortality and significant differences in behavioral tests have been reported in the offspring of male

rodents that were treated with methadone prior to mating when compared to control animals. Methadone has been detected in human amniotic fluid and cord plasma at concentrations proportional to maternal plasma and in newborn urine at lower concentrations than corresponding maternal urine. DISKETs Dispersible Tablets should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.

#### Dosage Adjustment During Pregnancy

The disposition of oral methadone has been studied in approximately 30 pregnant patients in 2nd and 3rd trimesters. Total body clearance of methadone was increased in pregnant patients compared to the same patients postpartum or to non-pregnant opioid-dependent women. The terminal half-life of methadone is decreased during 2nd and 3rd trimesters. The decrease in plasma half-life and increased clearance of methadone resulting in lower methadone trough levels during pregnancy can lead to withdrawal symptoms in some pregnant patients. The dosage may need to be increased or the dosing interval decreased in pregnant patients receiving DISKETs Dispersible Tablets to achieve therapeutic effect [see *Dosage and Administration (2.6)*].

#### Effect on the Neonate

Babies born to mothers who have been taking opioids regularly prior to delivery may be physically dependent. Onset of withdrawal symptoms in infants is usually in the first days after birth. Monitor newborn for withdrawal signs and symptoms including: irritability and excessive crying, tremors, hyper-active reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the neonatal withdrawal syndrome does not always correlate with the maternal dose or the duration of maternal exposure. The duration of the withdrawal signs may vary from a few days to weeks or even months. There is no consensus on the appropriate management of infant withdrawal [see *Use in Specific Populations (8.6)*].

#### Human Data

Reported studies have generally compared the benefit of methadone to the risk of untreated addiction to illicit drugs. Pregnant women involved in methadone maintenance programs have been reported to have significantly improved prenatal care leading to significantly reduced incidence of obstetric and fetal complications and neonatal morbidity and mortality when compared to women using illicit drugs. Several factors, including maternal use of illicit drugs, nutrition, infection and psychosocial circumstances, complicate the interpretation of investigations of the children of women who take methadone during pregnancy. Information is limited regarding dose and duration of methadone use during pregnancy, and most maternal exposure appears to occur after the first trimester of pregnancy.

A review of published data on experiences with methadone use during pregnancy by the Teratogen Information System (TERIS) concluded that maternal use of methadone during pregnancy as part of a supervised, therapeutic regimen is unlikely to pose a substantial teratogenic risk (quantity and quality of data assessed as “limited to fair”). However, the data are insufficient to state that there is no risk (TERIS, last reviewed October, 2002). A retrospective case series of 101 pregnant, opioid-dependent women who underwent inpatient opiate detoxification with methadone did not demonstrate any increased risk of miscarriage in the 2nd trimester or premature delivery in the 3rd trimester. Recent studies suggest an increased risk of premature delivery in opioid-dependent women exposed to methadone during pregnancy, although the presence of confounding factors makes it difficult to determine a causal relationship. Several studies have suggested that infants born to narcotic-addicted women treated with methadone during all or part of pregnancy have been found to have decreased fetal growth with reduced birth weight, length, and/or head circumference compared to controls. This growth deficit does not appear to persist into later childhood. Children prenatally exposed to methadone have been reported to demonstrate mild but persistent deficits in performance on psychometric and behavioral tests. In addition, several studies suggest that children born to opioid-dependent women exposed to methadone during pregnancy may have an increased risk of visual development anomalies; however, a causal relationship has not been assigned.

There are conflicting reports on whether Sudden Infant Death Syndrome occurs with an increased incidence in

infants born to women treated with methadone during pregnancy. Abnormal fetal non-stress tests have been reported to occur more frequently when the test is performed 1 to 2 hours after a maintenance dose of methadone in late pregnancy compared to controls.

#### Animal Data

Methadone did not produce teratogenic effects in rat or rabbit models. Methadone produced teratogenic effects following large doses, in the guinea pig, hamster, and mouse. One published study in pregnant hamsters indicated that a single subcutaneous dose of methadone ranging from 31 to 185 mg/kg (the 31 mg/kg dose is approximately 2 times a human daily oral dose of 120 mg/day on a mg/m<sup>2</sup> basis) on day 8 of gestation resulted in a decrease in the number of fetuses per litter and an increase in the percentage of fetuses exhibiting congenital malformations described as exencephaly, cranioschisis, and “various other lesions.” The majority of the doses tested also resulted in maternal death. In another study, a single subcutaneous dose of 22 to 24 mg/kg methadone (estimated exposure was approximately equivalent to a human daily oral dose of 120 mg/day on a mg/m<sup>2</sup> basis) administered on day 9 of gestation in mice also produced exencephaly in 11% of the embryos. However, no effects were reported in rats and rabbits at oral doses up to 40 mg/kg (estimated exposure was approximately 3 and 6 times, respectively, a human daily oral dose of 120 mg/day on a mg/m<sup>2</sup> basis) administered during days 6 to 15 and 6 to 18, respectively.

Published animal data have reported increased neonatal mortality in the offspring of male rodents that were treated with methadone prior to mating. In these studies, the female rodents were not treated with methadone, indicating paternally-mediated developmental toxicity. Specifically, methadone administered to the male rat prior to mating with methadone-naïve females resulted in decreased weight gain in progeny after weaning. The male progeny demonstrated reduced thymus weights, whereas the female progeny demonstrated increased adrenal weights. Behavioral testing of these male and female progeny revealed significant differences in behavioral tests compared to control animals, suggesting that paternal methadone exposure can produce physiological and behavioral changes in progeny in this model. Other animal studies have reported that perinatal exposure to opioids including methadone alters neuronal development and behavior in the offspring. Perinatal methadone exposure in rats has been linked to alterations in learning ability, motor activity, thermal regulation, nociceptive responses and sensitivity to drugs.

Additional animal data demonstrates evidence for neurochemical changes in the brains of methadone-treated offspring, including changes to the cholinergic, dopaminergic, noradrenergic and serotonergic systems. Studies demonstrated that methadone treatment of male rats for 21 to 32 days prior to mating with methadone-naïve females did not produce any adverse effects, suggesting that prolonged methadone treatment of the male rat resulted in tolerance to the developmental toxicities noted in the progeny. Mechanistic studies in this rat model suggest that the developmental effects of “paternal” methadone on the progeny appear to be due to decreased testosterone production. These animal data mirror the reported clinical findings of decreased testosterone levels in human males on methadone maintenance therapy for opioid addiction and in males receiving chronic intraspinal opioids.

Additional data have been published indicating that methadone treatment of male rats (once a day for three consecutive days) increased embryoletality and neonatal mortality. Examination of uterine contents of methadone-naïve female mice bred to methadone-treated mice indicated that methadone treatment produced an increase in the rate of preimplantation deaths in all post-meiotic states.

## 8.2 Labor and Delivery

Methadone is not for use in women during and immediately prior to labor. Opioid analgesics may prolong labor by temporarily reducing the strength, duration and frequency of uterine contractions. However, these effects are not consistent and may be offset by an increased rate of cervical dilatation, which tends to shorten labor.

Opioids with mixed agonist-antagonist properties should not be used for pain control during labor in patients chronically treated with methadone as they may precipitate acute withdrawal [*see Drug Interactions (7.4)*].

Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. Closely observe neonates whose mothers received opioid analgesics during labor for signs of respiratory depression. An opioid antagonist, such as naloxone, should be available for reversal of opioid-induced respiratory depression in the neonate.

### **8.3 Nursing Mothers**

Methadone is secreted into human milk. At maternal oral doses of 10 to 80 mg/day, methadone concentrations from 50 to 570 mcg/L in milk have been reported, which, in the majority of samples, were lower than maternal serum drug concentrations at steady state. Peak methadone levels in milk occur approximately 4 to 5 hours after an oral dose. Based on an average milk consumption of 150 mL/kg/day, an infant would consume approximately 17.4 mcg/kg/day which is approximately 2 to 3% of the oral maternal dose. Methadone has been detected in very low plasma concentrations in some infants whose mothers were taking methadone. Cases of sedation and respiratory depression in infants exposed to methadone through breast milk have been reported. Caution should be exercised when DISKETTS Dispersible Tablets are administered to a nursing woman.

Advise women who are being treated with DISKETTS Dispersible Tablets and who are breastfeeding or express a desire to breastfeed of the presence of methadone in human milk. Instruct breastfeeding mothers how to identify respiratory depression and sedation in their babies and when it may be necessary to contact their healthcare provider or seek immediate medical care. Breastfed infants of mothers using methadone should be weaned gradually to prevent development of withdrawal symptoms in the infant.

### **8.4 Pediatric Use**

The safety, effectiveness, and pharmacokinetics of methadone in pediatric patients below the age of 18 years have not been established.

### **8.5 Geriatric Use**

Clinical studies of methadone did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently compared to younger subjects. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, start elderly at the low end of the dosing range, taking into account the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy in geriatric patients. Closely monitor elderly patients for signs of respiratory and central nervous system depression.

### **8.6 Neonatal Opioid Withdrawal Syndrome**

Chronic maternal use of methadone during pregnancy can affect the fetus with subsequent withdrawal signs. Neonatal withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight. The onset, duration and severity of neonatal withdrawal syndrome vary based on the drug used, duration of use, the dose of last maternal use, and rate of elimination drug by the newborn. Neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening and should be treated according to protocols developed by neonatology experts.

## 8.7 Renal Impairment

Methadone pharmacokinetics have not been extensively evaluated in patients with renal insufficiency. Since unmetabolized methadone and its metabolites are excreted in urine to a variable degree, start these patients on lower doses and with longer dosing intervals and titrate slowly while carefully monitoring for signs of respiratory and central nervous system depression.

## 8.8 Hepatic Impairment

Methadone pharmacokinetics have not been extensively evaluated in patients with hepatic insufficiency. Methadone is metabolized by hepatic pathways; therefore, patients with liver impairment may be at risk of increased systemic exposure to methadone after multiple dosing. Start these patients on lower doses and titrate slowly while carefully monitoring for signs of respiratory and central nervous system depression.

## 9 DRUG ABUSE AND DEPENDENCE

### 9.1 Controlled Substance

Methadone is a mu-agonist opioid with an abuse liability similar to other opioid agonists and is a Schedule II controlled substance. Methadone and other opioids have the potential for being abused and are subject to criminal diversion [*see Warnings and Precautions (5.4)*].

### 9.2 Abuse

Drug abuse is the intentional non-therapeutic use of an over-the-counter or prescription drug, even once, for its rewarding psychological or physiological effects. Drug abuse includes, but is not limited to the following examples: the use of a prescription or over-the-counter drug to get “high”, or the use of steroids for performance enhancement and muscle build up.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and include: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.

“Drug-seeking” behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated claims of lost prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping” (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction. Preoccupation with achieving adequate pain relief can be appropriate behavior in a patient with poor pain control.

Abuse and addiction are separate and distinct from physical dependence and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction.

Methadone, like other opioids, can be diverted for non-medical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests as required by state law, is strongly advised.

Abuse of methadone poses a risk of overdose and death. This risk is increased with concurrent abuse of methadone with alcohol and other substances. DISKETS Dispersible Tablets are intended for oral use only and

must not be injected. Parenteral drug abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

Proper assessment and selection of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

DISKETTS Dispersible Tablets, when used for the treatment of opioid addiction in detoxification or maintenance programs, may be dispensed only by opioid treatment programs certified by the Substance Abuse and Mental Health Services Administration (and agencies, practitioners, and institutions by formal agreements with the program sponsor).

### 9.3 Dependence

Both tolerance and physical dependence can develop during chronic opioid therapy.

Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.

Physical dependence results in withdrawal symptoms after abrupt discontinuation or significant dose reduction of a drug. Withdrawal is also precipitated through the administration of drugs with opioid antagonist activity, e.g., naloxone, or mixed agonist/antagonist analgesics (pentazocine, butorphanol, buprenorphine, nalbuphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage. Physical dependence is expected during opioid agonist therapy of opioid addiction.

DISKETTS Dispersible Tablets should not be abruptly discontinued [*see Dosage and Administration (2.3, 2.4)*]. If DISKETTS Dispersible Tablets are abruptly discontinued in a physically dependent patient, an abstinence syndrome may occur. Some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, and mydriasis. Other symptoms also may develop, including irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.

Infants born to mothers physically dependent on opioids may also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms [*see Use in Specific Populations (8.1, 8.6)*].

## 10 OVERDOSAGE

### *Clinical Symptoms*

Acute overdose of methadone is manifested by respiratory depression, somnolence progressing to stupor or coma, maximally constricted pupils, skeletal-muscle flaccidity, cold and clammy skin, and sometimes, bradycardia and hypotension. In severe overdose, particularly by the intravenous route, apnea, circulatory collapse, cardiac arrest, and death may occur.

### *Treatment of Overdose*

In case of overdose, priorities are the re-establishment of a patent and protected airway and institution of assisted or controlled ventilation if needed. Employ other supportive measures (including oxygen, vasopressors) in the management of circulatory shock and pulmonary edema as indicated. Cardiac arrest or arrhythmias will require advanced life support techniques.

The opioid antagonists, such as naloxone, are available as specific antidotes to respiratory depression resulting from opioid overdose. Opioid antagonists should not be administered in the absence of clinically significant


respiratory or circulatory depression secondary to methadone overdose. Such agents should be administered cautiously to patients who are known, or suspected to be, physically dependent on methadone. In such cases, an abrupt or complete reversal of opioid effects may precipitate an acute withdrawal syndrome.

Because the duration of reversal would be expected to be less than the duration of action of methadone, carefully monitor the patient until spontaneous respiration is reliably re-established. If the response to opioid antagonists is suboptimal or not sustained, additional antagonist should be given as directed in the product's prescribing information.

In an individual physically dependent on opioids, administration of an opioid receptor antagonist may precipitate an acute withdrawal. The severity of the withdrawal produced will depend on the degree of physical dependence and the dose of the antagonist administered. If a decision is made to treat serious respiratory depression in the physically dependent patient, administration of the antagonist should be begun with care and by titration with smaller than usual doses of the antagonist.

## 11 DESCRIPTION

Methadone hydrochloride is chemically described as 6-(dimethylamino)-4,4-diphenyl-3-heptanone hydrochloride. Methadone hydrochloride is a white, essentially odorless, bitter-tasting crystalline powder. It is very soluble in water, soluble in isopropanol and in chloroform, and practically insoluble in ether and in glycerine. It is present in DISKETS Dispersible Tablets as the racemic mixture. Methadone hydrochloride has a melting point of 235°C, a pKa of 8.25 in water at 20°C, a solution (1 part per 100) pH between 4.5 and 6.5, a partition coefficient of 117 at pH 7.4 in octanol/water and a molecular weight of 345.91. Its molecular formula is  $C_{21}H_{27}NO \cdot HCl$  and its structural formula is:



Each DISKETS Dispersible Tablet contains 40 mg of methadone hydrochloride, USP and the following inactive ingredients: colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose, orange lake color, orange-pineapple flavor, potassium phosphate monobasic, pregelatinized starch, and stearic acid.

DISKETS Dispersible Tablets are cross-scored, allowing for flexible dosage adjustment. Each tablet may be broken or cut in half to yield two 20-mg doses, or in quarters to yield four 10-mg doses.

DISKETS Dispersible Tablets (Methadone Hydrochloride Tablets for Oral Suspension, USP), are for oral administration following dispersion in a liquid.

DISKETS Dispersible Tablets contain insoluble excipients and must not be injected.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Methadone hydrochloride is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs

composed of smooth muscle. The methadone withdrawal syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.

Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone's efficacy is unknown. Other NMDA receptor antagonists have been shown to produce neurotoxic effects in animals.

### 12.3 Pharmacokinetics

#### *Absorption*

Following oral administration the bioavailability of methadone ranges between 36 to 100% and peak plasma concentrations are achieved between 1 to 7.5 hours. Dose proportionality of methadone pharmacokinetics is not known. However, after administration of daily oral doses ranging from 10 to 225 mg, the steady-state plasma concentrations ranged between 65 to 630 ng/mL and the peak concentrations ranged between 124 to 1255 ng/mL. Effect of food on the bioavailability of methadone has not been evaluated.

#### *Distribution*

Methadone is a lipophilic drug and the steady-state volume of distribution ranges between 1.0 to 8.0 L/kg. In plasma, methadone is predominantly bound to  $\alpha$ 1-acid glycoprotein (85% to 90%). Methadone is secreted in saliva, breast milk, amniotic fluid and umbilical cord plasma.

#### *Metabolism*

Methadone is primarily metabolized by N-demethylation to an inactive metabolite, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP). Cytochrome P450 enzymes, primarily CYP3A4, CYP2B6, and CYP2C19 and to a lesser extent CYP2C9 and CYP2D6, are responsible for conversion of methadone to EDDP and other inactive metabolites, which are excreted mainly in the urine. Methadone appears to be a substrate for P-glycoprotein but its pharmacokinetics do not appear to be significantly altered in case of P-glycoprotein polymorphism or inhibition.

#### *Excretion*

The elimination of methadone is mediated by extensive biotransformation, followed by renal and fecal excretion. Published reports indicate that after multiple dose administration the apparent plasma clearance of methadone ranged between 1.4 and 126 L/h, and the terminal half-life ( $T_{1/2}$ ) was highly variable and ranged between 8 to 59 hours in different studies. Methadone is a basic ( $pK_a=9.2$ ) compound and the pH of the urinary tract can alter its disposition in plasma. Also, since methadone is lipophilic, it has been known to persist in the liver and other tissues. The slow release from the liver and other tissues may prolong the duration of methadone action despite low plasma concentrations.

#### *Drug Interactions*

##### *Cytochrome P450 Interactions*

Methadone undergoes hepatic N-demethylation by cytochrome P450 (CYP) isoforms, principally CYP3A4, CYP2B6, CYP2C19, and to a lesser extent by CYP2C9 and CYP2D6. Coadministration of methadone with CYP inducers may result in more rapid metabolism and potential for decreased effects of methadone, whereas administration with CYP inhibitors may reduce metabolism and potentiate methadone's effects. Although antiretroviral drugs such as efavirenz, nelfinavir, nevirapine, ritonavir, lopinavir+ritonavir combination are known to inhibit some CYPs, they are shown to reduce the plasma levels of methadone, possibly due to CYP induction activity [see *Drug Interactions (7.1)*]. Therefore, drugs administered concomitantly with methadone should be evaluated for interaction potential; clinicians are advised to evaluate individual response to drug therapy.

### Cytochrome P450 Inducers

The following drug interactions were reported following coadministration of methadone with known inducers of cytochrome P450 enzymes:

*Rifampin:* In patients well-stabilized on methadone, concomitant administration of rifampin resulted in a marked reduction in serum methadone levels and a concurrent appearance of withdrawal symptoms.

*Phenytoin:* In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg twice daily initially for 1 day followed by 300 mg daily for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. Upon discontinuation of phenytoin, the incidence of withdrawal symptoms decreased and methadone exposure increased to a level comparable to that prior to phenytoin administration.

*St. John's Wort, Phenobarbital, Carbamazepine:* Administration of methadone with other CYP3A4 inducers may result in withdrawal symptoms.

### Cytochrome P450 Inhibitors

Since the metabolism of methadone is mediated primarily by CYP3A4 isozyme, coadministration of drugs that inhibit CYP3A4 activity may cause decreased clearance of methadone.

*Voriconazole:* Repeat dose administration of oral voriconazole (400 mg every 12 hours for 1 day, then 200 mg every 12 hours for 4 days) increased the peak plasma concentration ( $C_{max}$ ) and AUC of (R)-methadone by 31% and 47%, respectively, in subjects receiving a methadone maintenance dose (30 to 100 mg daily). The  $C_{max}$  and AUC of (S)-methadone increased by 65% and 103%, respectively. Increased plasma concentrations of methadone have been associated with toxicity including QT prolongation. Frequent monitoring for adverse events and toxicity related to methadone is recommended during coadministration. Dose reduction of methadone may be needed [see *Drug Interactions (7.1)*].

### Antiretroviral drugs:

Although antiretroviral drugs such as efavirenz, nelfinavir, nevirapine, ritonavir, telaprevir, lopinavir+ritonavir combination are known to inhibit some CYPs, they are shown to reduce the plasma levels of methadone, possibly due to CYP induction activity.

*Abacavir, amprenavir, darunavir+ritonavir, efavirenz, nelfinavir, nevirapine, ritonavir, telaprevir, lopinavir+ritonavir, saquinavir+ritonavir, tipranvir+ritonavir combination:* Coadministration of these anti-retroviral agents resulted in increased clearance or decreased plasma levels of methadone [see *Drug Interactions (7.1)*].

*Didanosine and Stavudine:* Methadone decreased the AUC and peak levels for didanosine and stavudine, with a more significant decrease for didanosine. Methadone disposition was not substantially altered [see *Drug Interactions (7.1)*].

*Zidovudine:* Methadone increased the AUC of zidovudine which could result in toxic effects [see *Drug Interactions (7.1)*].

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

#### *Carcinogenesis*

The results of carcinogenicity assessment in B6C2F1 mice and Fischer 344 rats following dietary administration of two doses of methadone HCl have been published. Mice consumed 15 mg/kg/day or 60 mg/kg/day

methadone for two years. These doses were approximately 0.6 and 2.5 times a human daily oral dose of 120 mg/day on a body surface area basis (mg/m<sup>2</sup>). There was a significant increase in pituitary adenomas in female mice treated with 15 mg/kg/day but not with 60 mg/kg/day. Under the conditions of the assay, there was no clear evidence for a treatment-related increase in the incidence of neoplasms in male rats. Due to decreased food consumption in males at the high dose, male rats consumed 16 mg/kg/day and 28 mg/kg/day of methadone for two years. These doses were approximately 1.3 and 2.3 times a human daily oral dose of 120 mg/day, based on body surface area comparison. In contrast, female rats consumed 46 mg/kg/day or 88 mg/kg/day for two years. These doses were approximately 3.7 and 7.1 times a human daily oral dose of 120 mg/day, based on body surface area comparison. Under the conditions of the assay, there was no clear evidence for a treatment-related increase in the incidence of neoplasms in either male or female rats.

### *Mutagenesis*

There are several published reports on the potential genetic toxicity of methadone. Methadone tested positive in the *in vivo* mouse dominant lethal assay and the *in vivo* mammalian spermatogonial chromosome aberration test. Additionally, methadone tested positive in the *E. coli* DNA repair system and *Neurospora crassa* and mouse lymphoma forward mutation assays. In contrast, methadone tested negative in tests for chromosome breakage and disjunction and sex-linked recessive lethal gene mutations in germ cells of *Drosophila* using feeding and injection procedures.

### *Fertility*

Published animal studies show that methadone treatment of males can alter reproductive function. Methadone produces a significant regression of sex accessory organs and testes of male mice and rats.

## **16 HOW SUPPLIED/STORAGE AND HANDLING**

### **16.1 Storage and Handling**

DISKETTS Dispersible Tablets contain methadone which is a controlled substance. Like fentanyl, morphine, oxycodone, hydromorphone, and oxymorphone, methadone is controlled under Schedule II of the Federal Controlled Substances Act. DISKETTS Dispersible Tablets may be targeted for theft and diversion by criminals [see *Warnings and Precautions (5.4)*].

DISKETTS Dispersible Tablets, if dispensed, must be packaged in child-resistant containers and kept out of reach of children to prevent accidental ingestion.

Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

### **16.2 How Supplied**

DISKETTS Dispersible Tablets (Methadone Hydrochloride Tablets for Oral Suspension, USP)

**40 mg Tablets:** peach, cross-scored tablets (Identified 54 883)  
NDC 0054-4538-25: Bottles of 100 dispersible tablets.

**DEA order form required.**

## 17 PATIENT COUNSELING INFORMATION

Provide the following information to patients receiving DISKETTS Dispersible Tablets or their caregivers:

### Life-Threatening Respiratory Depression

Discuss the risk of respiratory depression with patients, explaining that the risk is greatest when starting DISKETTS Dispersible Tablets or when the dose is increased. Advise patients how to recognize respiratory depression and to seek medical attention if they are experiencing breathing difficulties.

### Symptoms of Arrhythmia

Instruct patients to seek medical attention immediately if they experience symptoms suggestive of an arrhythmia (such as palpitations, near syncope, or syncope) when taking DISKETTS Dispersible Tablets.

### Accidental Exposure

Instruct patients to take steps to store DISKETTS Dispersible Tablets securely. Accidental ingestion especially in children, may result in serious harm or death. Advise patients to dispose of unused DISKETTS Dispersible Tablets by flushing the tablets down the toilet.

### Abuse Potential

Inform patients that DISKETTS Dispersible Tablets contain methadone, a Schedule II controlled substance that is subject to abuse. Instruct patients not to share DISKETTS Dispersible Tablets with others and to take steps to protect DISKETTS Dispersible Tablets from theft or misuse.

### Risks from Concomitant Use of Alcohol and other CNS Depressants

Inform patients that the concomitant use of alcohol with methadone can increase the risk of life-threatening respiratory depression. Instruct patients not to consume alcoholic beverages, as well as prescription and over-the-counter drug products that contain alcohol, during treatment with DISKETTS Dispersible Tablets.

Inform patients that potentially serious additive effects may occur if methadone is used with other CNS depressants, and not to use such drugs unless supervised by a health care provider.

### Important Administration Instructions

Instruct patients how to properly take DISKETTS Dispersible Tablets, including the following:

- DISKETTS Dispersible Tablets are for oral administration only and must be initially dispersed in liquid before use. After dispersion in liquid, the preparation **must not be injected**.
- Inform patients that DISKETTS Dispersible Tablets should be taken only as directed to reduce the risk of life-threatening adverse reactions (e.g., respiratory depression), and the dose should not be adjusted without consulting a physician or other healthcare professional.
- Reassure patients initiating treatment with DISKETTS Dispersible Tablets for opioid dependence that the dose of methadone will “hold” for longer periods of time as treatment progresses.
- Apprise patients seeking to discontinue treatment with methadone for opioid dependence of the high risk of relapse to illicit drug use associated with discontinuation of DISKETTS Dispersible Tablets maintenance treatment.
- Advise patients not to discontinue DISKETTS Dispersible Tablets without first discussing the need for a tapering regimen with the prescriber.

### Hypotension

Inform patients that DISKETTS Dispersible Tablets may cause orthostatic hypotension and syncope. Instruct patients on how to recognize symptoms of low blood pressure and how to reduce the risk of serious consequences should hypotension occur (e.g., sit or lie down, carefully rise from a sitting or lying position).

Driving or Operating Heavy Machinery

Inform patients that DISKETS Dispersible Tablets may impair the ability to perform potentially hazardous activities such as driving or operating heavy machinery. Advise patients not to perform such tasks until they know how they will react to the medication.

Constipation

Advise patients of the potential for severe constipation, including management instructions and when to seek medical attention.

Anaphylaxis

Inform patients that anaphylaxis has been reported with ingredients contained in DISKETS Dispersible Tablets. Advise patients how to recognize such a reaction and when to seek medical attention.

Pregnancy

Advise female patients that DISKETS Dispersible Tablets can cause fetal harm and to inform the prescriber if they are pregnant or plan to become pregnant.

Breastfeeding

Instruct nursing mothers using DISKETS Dispersible Tablets to watch for signs of methadone toxicity in their infants, which include increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to their baby's healthcare provider immediately if they notice these signs. If they cannot reach the healthcare provider right away, instruct them to take the baby to the emergency room or call 911 (or local emergency services).

10005657/02

Boehringer Ingelheim  
Roxane Laboratories

